Changes in Beneficial Ownership · 4
Actuate Therapeutics, Inc.
ACTUNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-28
- Issuer
- ACTUATE THERAPEUTICS, INC.
- Issuer CIK
- 0001652935
- Trading symbol
- ACTU
Reporting owner 1
- Name
- SCHMITT DANIEL M
- Reporting owner CIK
- 0001318470
- Relationship
- Director · Officer
- Officer title
- President, CEO and Director
- Address
- C/O ACTUATE THERAPEUTICS, INC., 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-28 | P · Form 4 | 140,844[F1] | A | .355 | 442,560 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 564,071 | I | By The Schmitt Family Irrevocable Trust, dated December 31, 2019[F3] |
| Common Stock | 22,223 | I | By The Andrew Schmitt Irrevocable Trust, dated December 31, 2019[F4] |
| Common Stock | 22,223 | I | By The Anna Schmitt Irrevocable Trust, dated December 31, 2019[F5] |
| Common Stock | 22,223 | I | By The Edward Schmitt Irrevocable Trust, dated December 31, 2019[F6] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | 0.45 | 2026-10-28 | P · Form 4 | 70,422 | A | 0[F2] | 2026-10-28 | 2031-10-28 | Common Stock | 70,422 | 70,422 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents shares of common stock purchased on October 28, 2026 in connection with Issuers public offering.↩ 1
- F2
- Represents detachable warrants acquired on October 28, 2026 in connection with Issuers public offering. For every two shares of common stock acquired in connection with the public offering, one detachable warrant was issued for no additional consideration. The warrant is immediately exercisable and expires 5 years from this issuance date.↩ 1
- F3
- Represents shares held by The Schmitt Family Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee (the "Schmitt Family Trust").↩ 1
- F4
- Represents shares held by The Andrew Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.↩ 1
- F5
- Represents shares held by The Anna Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.↩ 1
- F6
- Represents shares held by The Edward Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.↩ 1
Signature 1
- Signed
- /s/ Paul Lytle, Attorney-in-Fact
- Date
- 2026-10-29
Company context
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (“GSK-3β”), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development.